Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Glycomed Inc. preclinical data

The Alameda, Calif., company discussed its new compounds at the meeting of the American Chemical Society in Washington, saying that several of the

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE